Clinical Trial Update: Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the antiarrhythmic and symptomatic effects of an antisense therapy targeting C-reactive protein in paroxysmal atrial fibrillation; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• ISIS CRP Rx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Paroxysmal Atrial Fibrillation | Phase 2 | Status: COMPLETED